pSivida Corp Presentations at ARVO 2009
April 25, 2009
pSivida Corp. announced that seven abstracts describing its ophthalmic drug delivery products and technologies have been accepted by ARVO for presentation at the 2009 Annual Meeting.
The presentations will focus both on the development of pSivida’s next generation bioerodible technologies for ophthalmic drug delivery and on clinical results from the company’s Iluvien™ program in diabetic macular edema (DME), as well as ongoing work with the FDA approved device Retisert®.
pSivida has developed the only treatments currently approved by the U.S. Food and Drug Administration (FDA) for sustained back-of-the-eye drug delivery: Vitrasert® and Retisert, both of which are licensed to Bausch & Lomb, and the Iluvien product currently in fully enrolled Phase III clinical trials conducted by the Company’s licensing partner Alimera Sciences. The NDA filing for Iluvien remains on schedule for early 2010.
Read the full release.
- pSivida Announces Positive Results From The Two Phase 3 FAME™ Trials of Iluvien in Patients With Diabetic Macular Edema
- FDA Delays Approval of Iluvien to Treat Diabetic Macular Edema
- Icon Biosciences Starting New Trials of Sustained Release Drug Delivery for Post-Op Cataract Patients
- Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?
- Pfizer Ophthalmics and Bausch & Lomb Announce Co-Promotion Agreement Covering Xalatan, Alrex, Lotemax and Zylet
Comments
Jump down to form below to submit your own comments
